

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 April 2002 (18.04.2002)

PCT

(10) International Publication Number
WO 02/30963 A1

- (51) International Patent Classification: C07K 14/00, G01N 33/53, C12P 21/06 (74) Agents: BRUNELLE, Jan et al.; Exelixis, Inc., 170 Harbor Way, South San Francisco, CA 94083-0511 (US).
- (21) International Application Number: PCT/US01/31868 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 12 October 2001 (12.10.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/239,689 12 October 2000 (12.10.2000) US (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant: EXELIXIS, INC. [US/US]; 170 Harbor Way, P.O. Box 511, South San Francisco, CA 94083-0511 (US).
- (72) Inventors: OLLMANN, Michael, Martin; 8 Odessa Court, Redwood City, CA 94063 (US). KEEGAN, Kevin, Patrick; 7425 Charmant Drive #2702, San Diego, CA 92122 (US). STOUT, Thomas, J.; 128 Galewood Circle, San Francisco, CA 94131 (US). MATTHEWS, David; 2 Balceta Avenue, San Francisco, CA 94127 (US). JOLY, Alison; 3205 Monterey Street, San Mateo, CA 94403 (US).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/30963 A1

(54) Title: HUMAN ECT2 AND METHODS OF USE

(57) Abstract: Human Ect2 polypeptide, fragments and derivatives, along with vectors and host cells for expression and production of Ect2 polypeptide are provided. Various methods of screening for agents that modulate interaction of Ect2 with an Ect2 binding agent, including high throughput methods, are also provided.

Human Ect2 and Methods of Use

REFERENCE TO RELATED APPLICATIONS

- [0001] This Application claims priority to U.S. provisional patent application serial No. 60/239,689, filed October 12, 2000, the contents of which are hereby incorporated in its entirety.

BACKGROUND OF THE INVENTION

- [0002] The superfamily of small (21 kDa) GTP binding proteins (small G proteins) comprises 5 subfamilies: Ras, Rho, ADP ribosylation factors (ARFs), Rab, and Ran, which act as molecular switches to regulate numerous cellular responses. Members of the Rho family of GTPases, include RhoA, -B, and -C, Rac1 and -2, and Cdc42. Guanine nucleotide exchange factors (GEFs) activate Rho proteins by catalyzing the replacement of bound GDP with GTP. The GTP-bound form of Rho proteins specifically interact with their effectors or targets and transmit signals to downstream molecules. Rho proteins are inactivated through the hydrolysis of bound GTP to GDP by intrinsic GTPase activity, assisted by GTPase activating proteins (GAPs). The Rho family of GTPases participate in regulation of the actin cytoskeleton and cell adhesion, and are also involved in regulation of smooth muscle contraction, cell morphology, cell motility, neurite retraction, cytokinesis, and cell transformation (Hall, A. Science (1998) 279:509-514).
- [0003] Ect2, a transforming protein with sequence similarity to the dbl homology (DH) domain proteins, is a GEF that associates with a subset of the Rho family proteins: RhoA, Cdc42, and Rac1. Ect2 phosphorylation, which is required for its exchange activity, occurs during G2 and M phases. Human Ect2 is involved in the regulation of cytokinesis. The human ect2 gene is located on the long arm of chromosome 3, at 3q26 (Takai S, et al., Genomics (1995) 27(1):220-222), a region of increased copy number and expression in a large number of cancers (Bitter MA, et al., Blood (1985) 66(6):1362-1370; Kim DH, et al., Int J Cancer. (1995) 60(6):812-819; Brzoska PM, et al., Cancer Res. (1995) 55(14):3055-3059; Balsara BR, et al., Cancer Res. (1997) 57(11):2116-2120; Heselmeyer K, et al., Genes Chromosomes Cancer (1997) 19(4):233-240; Sonoda G, et al., Genes Chromosomes Cancer. (1997) 20(4):320-8). Data available from the National Cancer Institute (www.ncbi.nlm.nih.gov/ncicgap)

indicates that human ect2 is overexpressed in cancers of the ovary, uterus, parathyroid, testis, brain, and colon.

- [0004] The ect2 gene is conserved at the sequence and functional levels in mammals and insects. The *pebble* gene in *Drosophila* (GenBank ID # (GI) 5817603) is the orthologue of mouse (GI293331) and human ect2, and is required for initiation of cytokinesis (Lehner CF, J. Cell Sci. (1992) 103: 1021-1030; Prokopenko SN, et al., Genes Dev (1999) 13(17):2301-2314).

SUMMARY OF THE INVENTION

- [0005] The invention provides isolated human Ect2 protein and its splice variant as well as fragments and derivatives thereof. Vectors and host cells expressing Ect2 molecules, as well as methods of production of Ect2 and methods of production of cells for expressing Ect2 are also described.
- [0006] The invention further provides methods of screening for agents that modulate the interaction of an Ect2 polypeptide with an Ect2 binding target. In one aspect, the screening method comprises the steps of expressing a recombinant Ect2 polypeptide, incubating the polypeptide and the Ect2 binding target with a candidate agent and determining whether the candidate agent modulates the binding of the Ect2 polypeptide with the Ect2 binding target. Preferred modulating agents include Ect2-specific antibodies and small molecules identified in high throughput screens.
- [0007] The invention further provides novel high throughput assays to measure Ect2 activity.

DETAILED DESCRIPTION OF THE INVENTION

- [0008] The ability to screen or manipulate the genomes of model organisms provides a powerful means to analyze complex genetic pathways. In particular, overexpression screens in *Drosophila* enable quick identification of genes involved in the same or overlapping pathways as human genetic pathways (Rorth P., et al., Development (1998) 125:1049-1057; WO0015843). We performed an overexpression screen in *Drosophila* to identify genes that interact with the cyclin dependent kinase inhibitor, p21 (Bourne HR, et al., Nature (1990) 348(6297):125-132; Marshall CJ, Trends Genet (1991) 7(3):91-95). Pebble, the *Drosophila* orthologue of human Ect2, was identified as a suppressor of p21 overexpression. To our knowledge, there are no prior reports in the literature of a link between Ect2 and the G1 phase of the cell cycle, or any

evidence that suggests that overexpression of Ect2 can overcome a block in the cell cycle. Our identification of an Ect2 orthologue in the *Drosophila* p21 screen supports both conclusions. Thus, Ect2 is a valuable "target" that can be used to identify compounds and other agents that modulate its function, and thus have utility in treatment of disease or disorders associated with defective cell cycle progression at G1 phase, and in particular, defective p21 function.

Ect2 Nucleic Acids and Polypeptides

- [0009] We identified cDNA sequences of human ect2 and a splice variant (SEQ ID NO:1 and SEQ ID NO:3, respectively) through bioinformatic analysis of public databases and "contigging" several incomplete EST sequences (AW965920, AI916675, AW504786, BE080710, AW504433, BE080860, AW970802, AA279942, AA206473, AA313301). Northern Blot analysis of mRNA from tumor samples, using full or partial ect2 cDNA (SEQ ID Nos:1 and 3) sequences as probes (Current Protocol in Molecular Biology, Eds. Asubel, et al., Wiley Interscience, NY), can identify tumors that overexpress Ect2, and that, therefore, are amenable to treatment by inhibition of Ect2 function. Alternatively, quantitative PCR, such as the TaqMan® procedure (PE Applied Biosystems) is used for analysis of Ect2 expression in tumor samples.
- [0010] The term "Ect2 polypeptide" refers to a full-length Ect2 protein or a fragment or derivative thereof. A preferred Ect2 polypeptide comprises or consists of an amino acid sequence of SEQ ID NO:2 or 4, or a fragment or derivative thereof. Compositions comprising Ect2 polypeptides may consist essentially of the Ect2 protein, fragment, or derivative, or may comprise additional components (*e.g.* pharmaceutically acceptable carriers or excipients, culture media, *etc.*).
- [0011] Ect2 protein derivatives typically share a certain degree of sequence identity or sequence similarity with SEQ ID NOs:2 or 4, or a fragment thereof. As used herein, "percent (%) sequence identity" with respect to a specified subject sequence, or a specified portion thereof, is defined as the percentage of nucleotides or amino acids in the candidate derivative sequence identical with the nucleotides or amino acids in the subject sequence (or specified portion thereof), after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent sequence identity, as generated by the program WU-BLAST-2.0a19 (Altschul *et al.*, J. Mol. Biol. (1997) 215:403-410; <http://blast.wustl.edu/blast/README.html>) with search parameters set to default values. The HSP S and HSP S2 parameters are dynamic values and are

established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched. A "% identity value" is determined by the number of matching identical nucleotides or amino acids divided by the sequence length for which the percent identity is being reported. "Percent (%) amino acid sequence similarity" is determined by doing the same calculation as for determining % amino acid sequence identity, but including conservative amino acid substitutions in addition to identical amino acids in the computation. A conservative amino acid substitution is one in which an amino acid is substituted for another amino acid having similar properties such that the folding or activity of the protein is not significantly affected. Aromatic amino acids that can be substituted for each other are phenylalanine, tryptophan, and tyrosine; interchangeable hydrophobic amino acids are leucine, isoleucine, methionine, and valine; interchangeable polar amino acids are glutamine and asparagine; interchangeable basic amino acids are arginine, lysine and histidine; interchangeable acidic amino acids are aspartic acid and glutamic acid; and interchangeable small amino acids are alanine, serine, threonine, cysteine and glycine.

[0012] Preferred Ect2 protein derivatives or fragments share at least 80% sequence identity or similarity, preferably at least 85%, more preferably at least 90%, still more preferably at least 95%, and most preferably 97% or 100% sequence identity or similarity with a contiguous stretch of at least 25, 50, 100, 224, or 234 amino acids of SEQ ID NO:2 or 4, and in some cases, the entire length of SEQ ID NO:2 or 4. Preferred derivatives or fragments of Ect2 consist of or comprise an amino acid sequence that has at least 80%, preferably at least 85%, more preferably at least 90%, still more preferably at least 95%, and most preferably 100% sequence identity or sequence similarity with any of amino acid residues 147-227 (BRCT domain), 235-323 (BRCT domain), 327-330 (CDC2 consensus site), 419-617 (RHOGEF domain), 636-765 (PH domain), and 814-817 (CDC2 consensus site) of SEQ ID NO:2, or with any amino acid residues 178-258 (BRCT domain), 266-354 (BRCT domain), 358-361 (CDC2 consensus site), 450-648 (RHOGEF domain), 667-796 (PH domain), and 845-848 (CDC2 consensus site) of SEQ ID NO: 4. Each one of the above domains was identified using the pfam program (Bateman *et al.*, Nucleic Acids Res. (1999) 27:260-262; <http://pfam.wustl.edu/>), which also contains the detailed description of each domain (BRCT domain: PF00533; RHOGEF domain: PF00621; PH domain: PF00169).

[0013] The fragment or derivative of the Ect2 protein is preferably "functionally active" meaning that it exhibits one or more functional activities associated with a full-length, wild-type Ect2 protein comprising the amino acid sequence of SEQ ID NOs:2 or 4. As one example, a fragment or derivative may have antigenicity such that it can be used in immunoassays, for immunization, for modulation of Ect2 activity, *etc.*, as discussed further below regarding generation of antibodies to Ect2 proteins. Preferably, a functionally active Ect2 fragment or derivative is one that displays one or more biological activities associated with Ect2 proteins, such as signaling activity, binding to small GTPases and/or catalysis of GDP/GTP exchange in small GTPases. If Ect2 fragments are used in assays to identify modulating agents, the fragments preferably comprise one or more of the above-mentioned Ect2 domains, or a C- or N-terminus, and preferably comprise at least 10, 20, 25, 50, 224, or 234 contiguous amino acids of SEQ ID NO:1 or 2.

[0014] The term "Ect2 nucleic acid" refers to a DNA or RNA molecule that encodes an Ect2 polypeptide. Preferably, the Ect2 polypeptide or nucleic acid or fragment thereof is from a human (e.g. SEQ ID NOs 1-4), but it can be an ortholog or derivative thereof, preferably with at least 70%, 80%, 85%, 90%, or 95% sequence identity with any one of SEQ ID NOs 1-4. Orthologs can be identified by BLAST analysis using SEQ ID NO:2 or 4, using methods known in the art (Huynen MA and Bork P, *Proc Natl Acad Sci* (1998) 95:5849-5856; Huynen MA *et al.*, *Genome Research* (2000) 10:1204-1210).

Isolation, Production, and Expression of Ect2 Nucleic Acids and Polypeptides

[0015] A wide variety of methods are available for obtaining Ect2 polypeptides. In general, the intended use for the polypeptide will dictate the particulars of expression, production, and purification methods. For instance, production of polypeptides for use in screening for modulating agents may require methods that preserve specific biological activities of these proteins, whereas production of polypeptides for antibody generation may require structural integrity of particular epitopes. Expression of polypeptides to be purified for screening or antibody production may require the addition of specific tags (*i.e.*, generation of fusion proteins). Techniques for the expression, production, and purification of proteins are well known in the art; any suitable means therefor may be used (e.g., Higgins SJ and Hames BD (eds.) *Protein Expression: A Practical Approach*, Oxford University Press Inc., New York 1999;

Stanbury PF et al., Principles of Fermentation Technology, 2nd edition, Elsevier Science, New York, 1995; Doonan S (ed.) Protein Purification Protocols, Humana Press, New Jersey, 1996; Coligan JE et al, Current Protocols in Protein Science (eds.), 1999, John Wiley & Sons, New York; U.S. Pat. No. 6,165,992).

[0016] The nucleotide sequence encoding an Ect2 polypeptide can be inserted into any appropriate vector for expression of the inserted protein-coding sequence. The necessary transcriptional and translational signals, including promoter/enhancer element, can derive from the native ect2 gene and/or its flanking regions or can be heterologous. The ect2 gene may be expressed in prokaryotic or eukaryotic cells. The method of choice depends on the intended use of the protein. In particular, eukaryotic systems are particularly useful when native folding and posttranslational modifications are required. Preferred prokaryotic cells include *Escherichia coli* and *Bacillus subtilis*. Preferred eukaryotic cells include mammalian cells (such as human, mouse, monkey or Chinese hamster ovary cells), yeast cells (such as *Pichia* and *Saccharomyces* species) and insect cells (such as *Drosophila* and various lepidopteran cell lines, e.g. Sf9 cells). Cell extracts or supernatants may be purified in order to isolate the Ect2 polypeptide. Preferred purification techniques include HPLC, size exclusion chromatography, cation and anion exchange chromatography, reverse phase chromatography, affinity chromatography and other protein purification techniques known to those skilled in the art.

[0017] The Ect2 polypeptide may be optionally expressed as a fusion or chimeric product, joined via a peptide bond to a heterologous protein sequence. For example, to facilitate detection and/or purification of Ect2 polypeptide, the Ect2 expression vector construct may contain one or more antibody epitope coding sequences introduced at the N-terminus, C-terminus of the Ect2 coding region and/or at any position within the gene sequence. Suitable sequences include the Myc epitope, HA epitope, FLAG epitope or polyhistidine epitope (see, e.g. Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory). As another example, the Ect2 polypeptide may be expressed as a fusion protein joined to a transcriptional reporter such as GFP or luciferase. A chimeric protein can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other in the proper coding frame using standard methods and expressing the chimeric product. A chimeric protein may also be made by protein synthetic techniques, e.g. by use of a peptide synthesizer (Hunkapiller *et al.*, Nature (1984) 310:105-111).

Structural Analysis of Ect2

- [0018] Three-dimensional structures of components of the Ect2-G-protein (RhoA/Rac/CDC42) system as studied by single-crystal X-ray crystallography provide insight into the mechanistic details of protein-protein recognition between Ect2 and its target G-protein, the guanine nucleotide exchange activity, and the ability of small-molecule compounds to modulate this activity in a therapeutically beneficial manner.
- [0019] Various Ect2 polypeptide constructs can be studied by X-ray crystallography such as full-length wild-type human Ect2; full-length human Ect2 with relevant point mutations, as indicated by mechanistic biochemical assays; the sub-construct of the RhoGEF domain of human Ect2 (residues 419-617 of SEQ ID NO:2, or 450-648 of SEQ ID NO:4); constructs of the RhoGEF domain of human Ect2 containing relevant point mutations (enhancing, diminishing, or abrogating GEF activity); the sub-construct of the RhoGEF and PH domains of human Ect2 (residues 419-765 of SEQ ID NO:2, or 450-796 of SEQ ID NO:4); constructs of the RhoGEF and PH domains of human Ect2 containing relevant point mutations (enhancing, diminishing, or abrogating GEF activity); any of the above constructs in their native forms, or with N-terminal tags, or with N-terminal GST fusion proteins; any of the above constructs in phosphorylated or dephosphorylated form; and any of the aforementioned in complex with small-molecule modulators of GEF activity as selected from a compound library.
- [0020] The crystal structures of these Ect2 polypeptides and complexes are determined through the use of standard techniques (Bergfors, T., Ed., 1999, "Protein Crystallization: Techniques, Strategies, and Tips" International University Line, La Jolla, CA, USA). Crystallizations are accomplished through the screening of "crystallization space" using standard techniques of "Incomplete Factorial Screening" in a variety of crystallization geometries such as hanging drop, sitting drop, sandwich drop, capillary diffusion, gel equilibration, etc. (McPherson, A., 1989, "Preparation and Analysis of Protein Crystals" R.E.Krieger Publishing Co., Malabar, FL, USA). Diffraction data are collected from these crystals *via* the rotation method (Blundell, T.L., Johnson, L.N., 1976, "Protein Crystallography" Academic Press, Harcourt Brace Jovanovich, Publishers; London; Stout & Jensen, 1989, "X-ray Structure Determination, A Practical Guide" John Wiley & Sons, Publishers, New York) both on a rotating anode X-ray generator and at synchrotron sources. Crystal structures are determined by techniques standard in the field, such as molecular replacement (MR), heavy atom phasing *via* single isomorphous replacement (SIR), heavy atom phasing

via single isomorphous replacement with anomalous scattering (SIRAS), heavy atom phasing via multiple isomorphous replacement (MIR), heavy atom phasing via multiple isomorphous replacement with anomalous scattering (MIRAS), and/or heavy atom phasing via isomorphous replacement of methionines with selenomethionine and employing "Multiwavelength Anomalous Diffraction" (MAD) (Blundell & Johnson; *supra*; Stout & Jensen, *supra*; Bella, J.; Rossmann, M.G., 1998, Acta Crystallogr D Biol Crystallogr, 54(Pt 2), 159-74; Fanchon, E.; Hendrickson, W.A., Acta Crystallogr A, 1990, Oct 1, 46 (Pt 10):809-20; Hendrickson WA; et al., Proteins, 1988 4(2), 77-88; Pahler, A.; et al., 1990, Acta Crystallographica. Section A, Crystal physics, Diffraction, Theoretical and General Crystallography, 46 (Pt 7), 537-40; Terwilliger, T.C., Berendzen, J., 1999, Acta Crystallographica, Section D, Biological Crystallography, 55(Pt 4), 849-61; and Walsh, M.A., et al., 1999 Acta Crystallogr D Biol Crystallogr, 55(Pt 10), 1726-32).

Functional validation

- [0021] In general, functional assays are used to confirm the participation of the Ect2 gene and its orthologs in p21-related pathways. Various preferred assays for functional validation of Ect2 in the p21 pathway include expression analysis, and cell transformation, proliferation, cell cycle, apoptosis, and hypoxia induction assays, among others.
- [0022] A preferred functional validation assay for Ect2 is expression analysis. Several methods are available to assess whether altered Ect2 expression is correlated with tumorigenicity, or another p21-related phenotype. These include Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR, and microarray analysis. (e.g., Current Protocols in Molecular Biology (1994) Ausubel FM *et al.*, eds., John Wiley & Sons, Inc., chapter 4; Freeman WM *et al.*, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; BloMP21 DH and Guiseppi-Elie, ACurr Opin Biotechnol 2001, 12:41-47). In one example, Northern blot analysis of mRNA from tumor and normal cell lines, and from tumor and matching normal tissue samples from the same patients, using full or partial Ect2 cDNA sequences as probes, can determine whether particular tumors overexpress Ect2. Alternatively, the TaqMan® is used for quantitative RT-PCR analysis of Ect2 expression in cell lines, normal tissues and tumor samples (PE Applied Biosystems).

[0023] Apoptosis, cell proliferation, cell cycle, cell transformation, and hypoxia induction assays typically involve comparing these cellular events in wild type cells and cells with altered expression of an Ect2 protein. These assays may use tumor or other cells or cell lines with increased or decreased expression of an Ect2 protein, such as those identified by expression analysis, as described above. Alternatively, the assays may use cells engineered to specifically overexpress an Ect2 protein, using above-described expression methods. The assay may also use cells specifically engineered to disrupt expression of an Ect2 protein, such as by RNA inhibition (Elbashir SM et al. Nature 2001, 411: 494-498) or using antisense oligomers, as further described below.

[0024] Assays for apoptosis may be performed by terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling (TUNEL) assay. The TUNEL assay is used to measure nuclear DNA fragmentation characteristic of apoptosis (Lazebnik *et al.*, 1994, Nature 371, 346), by following the incorporation of fluorescein-dUTP (Yonehara *et al.*, 1989, J. Exp. Med. 169, 1747). Apoptosis may further be assayed by acridine orange staining of tissue culture cells (Lucas, R., et al., 1998, Blood 15:4730-41).

[0025] Cell proliferation may be assayed via bromodeoxyuridine (BRDU) incorporation. This assay identifies a cell population undergoing DNA synthesis by incorporation of BRDU into newly-synthesized DNA. Newly-synthesized DNA may then be detected using an anti-BRDU antibody (Hoshino *et al.*, 1986, Int. J. Cancer 38, 369; Campana *et al.*, 1988, J. Immunol. Meth. 107, 79). Cell Proliferation may also be examined using [³H]-thymidine incorporation (Chen, J., 1996, Oncogene 13:1395-403; Jeoung, J., 1995, J. Biol. Chem. 270:18367-73). This assay allows for quantitative characterization of S-phase DNA syntheses. In this assay, cells synthesizing DNA will incorporate [³H]-thymidine into newly synthesized DNA. Incorporation can then be measured by standard techniques such as by counting of radioisotope in a scintillation counter (e.g., Beckman LS 3800 Liquid Scintillation Counter). Cell proliferation may also be assayed by colony formation in soft agar (Sambrook et al., Molecular Cloning, Cold Spring Harbor (1989)). Cells transformed with Ect2 are seeded in soft agar plates, and colonies are measured and counted after two weeks incubation.

[0026] Angiogenesis may be assayed using various human endothelial cell systems, such as umbilical vein, coronary artery, or dermal cells. The assays might include Alamar Blue based assays (available from Biosource International) to measure proliferation; migration assays using fluorescent molecules, such as the use of Becton Dickinson

Falcon HTS FluoroBlock cell culture inserts to measure migration of cells through membranes in presence or absence of angiogenesis enhancer or suppressors; or tubule formation assays based on the formation of tubular structures by endothelial cells on Matrigel™ (Becton Dickinson).

[0027] Involvement of a gene in the cell cycle may be assayed by flow cytometry. Cells transfected with an Ect2 may be stained with propidium iodide and evaluated in a flow cytometer (available from Becton Dickinson).

[0028] Induction by hypoxic conditions may be assayed by growing cells transfected with MP21 in hypoxic conditions (such as with 0.1% O₂, 5% CO₂, and balance N₂, generated in a Napco 7001 incubator (Precision Scientific)) and normoxic conditions, followed by assessment of gene activity or expression by Taqman®.

Production of Genetically Modified Animals

[0029] The methods of this invention may use non-human animals that have been genetically modified to alter expression of Ect2 and/or other genes known to be involved in regulation of the G1 phase of the cell cycle, such as p21. Preferred genetically modified animals are mammals. Preferred non-mammalian species include Zebrafish, *C. elegans*, and *Drosophila*. Preferably, the altered Ect2 or other gene expression results in a detectable phenotype, such as increased or reduced cell proliferation relative to control animals having normal expression of the altered gene. The genetically modified animals can be used to further elucidate the p21 pathway, in animal models of pathologies associated with cell proliferation disorders, and for *in vivo* testing of candidate therapeutic agents, as described below.

[0030] Preferred genetically modified animals are transgenic, at least a portion of their cells harboring non-native nucleic acid that is present either as a stable genomic insertion or as an extra-chromosomal element, which is typically mosaic. Preferred transgenic animals have germ-line insertions that are stably transmitted to all cells of progeny animals.

[0031] Non-native nucleic acid is introduced into host animals by any expedient method. Methods of making transgenic non-human animals are well-known in the art (for mice see Brinster et al., Proc. Nat. Acad. Sci. USA 1985, 82:4438-42; U.S. Pat. Nos. 4,736,866, 4,870,009, 4,873,191, 6,127,598; Hogan, B., Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1986); for homologous recombination see Capecchi, Science 1989, 244:1288-1292; Joyner et al.,

Nature 1989, 338:153-156; for particle bombardment see U.S. Pat. No., 4,945,050; for *Drosophila* see Rubin and Spradling, Science (1982) 218:348-53, U.S. Pat. No. 4,670,388; for transgenic insects see Berghammer A.J. *et al.*, Nature 1999, 402:370-371; for Zebrafish see Lin S. Methods Mol Biol. (2000); 136:375-3830; for fish, amphibians and birds see Houdebine and Chourrout, Experientia (1991) 47:897-905; for rats see Hammer *et al.*, Cell (1990) 63:1099-1112; for embryonic stem (ES) cells see Teratocarcinomas and Embryonic Stem Cells, A Practical Approach, E. J. Robertson, ed., IRL Press (1987); for livestock see Pursel *et al.*, Science (1989) 244:1281-1288; for nonhuman animal clones see Wilmut, I. *et al.* (1997) Nature 385:810-813, PCT Publication Nos. WO 97/07668 and WO 97/07669; for recombinase systems for regulated transgene expression see, Lakso *et al.*, PNAS (1992) 89:6232-6236; U.S. Pat. No. 4,959,317 [for cre-loxP] and O'Gorman *et al.*, Science (1991) 251:1351-1355; U.S. Pat. No. 5,654,182 [for FLP/FRT].

- [0032] Homozygous or heterozygous alterations in the genomes of transgenic animals may result in mis-expression of native genes, including ectopic expression, over-expression (*e.g.* by multiple gene copies), under-expression, and non-expression (*e.g.* by gene knock-out or blocking expression that would otherwise normally occur). In one application, a "knock-out" animal is generated, typically using homologous recombination, in which an alteration in an endogenous gene causes a decrease in that gene's function, preferably such that gene expression is undetectable or insignificant.

Ect2-Modulating Agents

- [0033] The invention provides methods to identify agents that interact with and/or modulate the function of Ect2 and/or the p21 pathway. Such agents are useful in a variety of diagnostic and therapeutic applications associated with diseases or disorders involving a defective p21 pathway, as well as in further analysis of the Ect2 protein and its contribution to the p21 pathway. Accordingly, the invention also provides methods for modulating the p21 pathway comprising the step of specifically modulating Ect2 activity by administering Ect2-interacting or -modulating agent.
- [0034] In a preferred embodiment, Ect2-modulating agents inhibit or enhance Ect2 activity or otherwise affect normal Ect2 function, including transcription, protein expression, protein localization, and cellular or extra-cellular activity. In a further preferred embodiment, the candidate p21 pathway-modulating agent specifically modulates the function of the Ect2. The phrases "specific modulating agent",

"specifically modulates", etc., are used herein to refer to modulating agents that directly bind to the Ect2 polypeptide or nucleic acid, and preferably inhibit, enhance, or otherwise alter the function of the Ect2. The term also encompasses modulating agents that alter the interaction the Ect2 with a binding partner or substrate (e.g. by binding to a binding partner of an Ect2, or to a protein/binding partner complex, and inhibiting function).

[0035] Preferred Ect2-modulating agents include small molecule chemical agents, Ect2-interacting proteins, including antibodies and other biotherapeutics, and nucleic acid modulators, including antisense oligomers and RNA. The modulating agents may be formulated in pharmaceutical compositions, for example, as compositions that may comprise other active ingredients, as in combination therapy, and/or suitable carriers or excipients. Methods of formulating biotherapeutic agent are described in detail in U.S. Pat. No. 6,146,628. Techniques for formulation and administration of compounds may be found in "Remington's Pharmaceutical Sciences" Mack Publishing Co., Easton, PA, 19th edition.

Small Molecule Modulators

[0036] Small molecule modulators are typically organic, non-peptide molecules, having a molecular weight less than 10,000, preferably less than 5,000, more preferably less than 1,000, and most preferably less than 500. This class of modulators includes chemically synthesized molecules, for instance, compounds from combinatorial chemical libraries. Small molecule modulators may be rationally designed based on known structural properties, for example, discerned using method described above. Structures of Ect2 in complex with the partner G-protein (RhoA/Rac/CDC42) show the details of protein-protein interactions required for the GEF activity and can be used to aid in the rational design of small-molecule compounds that modulate the mechanics of these interactions, thereby disrupting the GEF functionality. Structures of Ect2 polypeptides in complex with small-molecule ligands which serve to modulate the GEF activity delineate the portions of the Ect2 molecule which are either directly involved in the catalytic active site or which exert an allosteric effect on the active site, thereby modulating the GEF activity. These modulators of Ect2/GEF activity bind within a radius of 25Å, 20Å, 15Å, 10Å, 5Å, or 1.8Å of certain residues, such as serine 571 (...RLPSVA...), thereby defining a productive binding mode that modulates GEF

activity. Small molecule modulators may also be identified by screening compound libraries.

[0037] Alternative small molecule modulators include natural products, particularly secondary metabolites from organisms such as plants or fungi, which can also be identified by screening compound libraries for Ect2-modulating activity. Methods for generating and obtaining compounds are well known in the art (Schreiber SL, Science (2000) 151: 1964-1969; Radmann J and Gunther J, Science (2000) 151:1947-1948).

[0038] Small molecule modulators identified from screening assays, as described below, can be used as lead compounds from which candidate clinical compounds may be designed, optimized, and synthesized. Such clinical compounds may have utility in treating pathologies associated with the defective p21 signaling. The activity of candidate small molecule modulating agents may be improved several-fold through iterative secondary functional validation, as further described below, structure determination, and candidate modulator modification and testing. Additionally, candidate clinical compounds are generated with specific regard to clinical and pharmacological properties. For example, the reagents may be derivatized and re-screened using *in vitro* and *in vivo* assays to optimize activity and minimize toxicity for pharmaceutical development.

Protein Modulators

[0039] An Ect2-interacting protein may be endogenous, *i.e.* one that normally interacts genetically or biochemically with an Ect2, such as a member of the p21 pathway that modulates Ect2 expression, localization, and/or activity. Ect2-modulators include dominant negative forms of Ect2-interacting proteins and of Ect2 proteins themselves. Yeast two-hybrid and variant screens offer preferred methods for identifying endogenous Ect2-interacting (Finley, R. L. et al. (1996) in DNA Cloning-Expression Systems: A Practical Approach, eds. Glover D. & Hames B. D (Oxford University Press, Oxford, England), pp. 169-203; Fashema SF et al., Gene (2000) 250:1-14; Drees BL Curr Opin Chem Biol (1999) 3:64-70; Vidal M and Legrain P Nucleic Acids Res (1999) 27:919-29; and U.S. Pat. No. 5,928,868). Mass spectrometry offers alternative preferred methods for the elucidation of protein complexes (reviewed in, *e.g.*, Pandley A and Mann M, Nature (2000) 405:837-846; Yates JR 3rd, Trends Genet (2000) 16:5-8).

[0040] An Ect2-interacting protein may be exogenous protein, such as an Ect2-specific antibody or a T-cell antigen receptor (see, e.g., Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory). Ect2 antibodies are further discussed below.

[0041] In one preferred embodiment, an Ect2-interacting protein specifically binds an Ect2 protein. In an alternative preferred embodiment an Ect2-modulating agent binds an Ect2 substrate, binding partner, or cofactor. In certain applications when Ect2-interacting proteins are used in screens to identify small molecule modulators, the binding specificity of the interacting protein to the Ect2 protein may be assayed by various known methods, including binding equilibrium constants (usually at least about 10^7 M^{-1} , preferably at least about 10^8 M^{-1} , more preferably at least about 10^9 M^{-1}), and immunogenic properties. For enzymes and receptors, binding may be assayed by, respectively, substrate and ligand processing.

Specific antibodies

[0042] In a preferred embodiment, the Ect2-interacting protein is an antibody. Antibodies that specifically bind Ect2 polypeptides can be generated using known methods. Preferably the antibody is specific to a mammalian Ect2 polypeptide, and more preferably, a human Ect2. Antibodies may be polyclonal, monoclonal (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, fragments produced by a FAb expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Monoclonal antibodies with affinities of 10^8 M^{-1} preferably 10^9 M^{-1} to 10^{10} M^{-1} , or stronger can be made by standard procedures as described (Harlow and Lane, *Antibodies: A Laboratory Manual*, CSH Laboratory (1988); Goding (1986) *Monoclonal Antibodies: Principles and Practice* (2d ed) Academic Press, New York; and U.S. Pat. Nos. 4,381,292; 4,451,570; and 4,618,577). Antibodies may be generated against extracts of cells that express Ect2 or from substantially purified Ect2 or fragments thereof. If Ect2 fragments are used, they preferably comprise at least 10, and more preferably, at least 20 contiguous amino acids of an Ect2 protein. In a particular embodiment Ect2-specific antigens and/or immunogens are coupled to carrier proteins that stimulate the immune response. For example, the subject polypeptides are covalently coupled to the keyhole limpet hemocyanin (KLH) carrier, and the conjugate is emulsified in Freund's complete adjuvant, which enhances the immune response. An appropriate immune

system such as a laboratory rabbit or mouse is immunized according to conventional protocols.

[0043] The presence of Ect2-specific antibodies is assayed by an appropriate assay such as a solid phase enzyme-linked immunosorbant assay (ELISA) using immobilized corresponding Ect2 polypeptides. Other assays, such as radioimmunoassays or fluorescent assays might also be used.

[0044] Chimeric antibodies specific to Ect2 polypeptides can be made that contain different portions from different animal species. For instance, a human immunoglobulin constant region may be linked to a variable region of a murine mAb, such that the antibody derives its biological activity from the human antibody, and its binding specificity from the murine fragment. Chimeric antibodies are produced by splicing together genes that encode the appropriate regions from each species (Morrison et al., Proc. Natl. Acad. Sci. (1984) 81:6851-6855; Neuberger et al., Nature (1984) 312:604-608; Takeda et al., Nature (1985) 31:452-454). Humanized antibodies, which are a form of chimeric antibodies, can be generated by grafting complementary-determining regions (CDRs) (Carlos, T. M., J. M. Harlan., Blood (1994) 84:2068-2101) of mouse antibodies into a background of human framework regions and constant regions by recombinant DNA technology (Riechmann LM, et al., Nature (1988) 323:323-327). Humanized antibodies contain ~10% murine sequences and ~90% human sequences, and thus further reduce or eliminate immunogenicity, while retaining the antibody specificities (Co MS, and Queen C., Nature (1991) 351:501-501; Morrison SL., Ann. Rev. Immun. (1992) 10:239-265). Humanized antibodies and methods of their production are well-known in the art (U.S. Pat Nos. 5,530,101; 5,585,089; 5,693,762, and 6,180,370).

[0045] Ect2-specific single chain antibodies, which are recombinant, single chain polypeptides formed by linking the heavy and light chain fragments of the Fv regions via an amino acid bridge, can be produced (U.S. Pat. No. 4,946,778; Bird, Science (1988) 242:423-426; Huston et al., Proc. Natl. Acad. Sci. USA (1988) 85:5879-5883; and Ward et al., Nature (1989) 334:544-546).

[0046] Other suitable techniques for antibody production involve in vitro exposure of lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors (Huse et al., Science (1989) 246:1275-1281).

[0047] The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, the polypeptides and antibodies will be labeled by

joining, either covalently or non-covalently, a substance that provides for a detectable signal, or that is toxic to cells that express the targeted protein (Menard S, et al., Int J. Biol Markers (1989) 4:131-134). A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, fluorescent emitting lanthanide metals, chemiluminescent moieties, bioluminescent moieties, magnetic particles, and the like (U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241). Also, recombinant immunoglobulins may be produced (U.S. Pat. No. 4,816,567). Antibodies to cytoplasmic proteins may be delivered and reach their targets by conjugation with membrane-penetrating toxin proteins (U.S. Pat. NO. 6,086,900).

[0048] When used therapeutically in a patient, the antibodies of the subject invention are typically administered parenterally, when possible at the target site, or intravenously. The therapeutically effective dose and dosage regimen is determined by clinical studies. Typically, the amount of antibody administered is in the range of about 0.1 mg/kg –to about 10 mg/kg of patient weight. For parenteral administration, the antibodies are formulated in a unit dosage injectable form (e.g., solution, suspension, emulsion) in association with a pharmaceutically acceptable vehicle. Such vehicles are inherently nontoxic and non-therapeutic. Examples are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Nonaqueous vehicles such as fixed oils, ethyl oleate, or liposome carriers may also be used. The vehicle may contain minor amounts of additives, such as buffers and preservatives, which enhance isotonicity and chemical stability or otherwise enhance therapeutic potential. The antibodies' concentrations in such vehicles are typically in the range of about 1 mg/ml –to about 10 mg/ml. Immunotherapeutic methods are further described in the literature (US Pat. No. 5,859,206; WO0073469).

Nucleic Acid Modulators

[0049] Other preferred Ect2-modulating agents comprise nucleic acid molecules, such as antisense oligomers or double stranded RNA (dsRNA), which generally inhibit Ect2 activity.

[0050] Preferred antisense oligomers interfere with the function of Ect2 nucleic acids, such as DNA replication, transcription, Ect2 RNA translocation, translation of protein from the Ect2 RNA, RNA splicing, and any catalytic activity in which the Ect2 RNA

participates. In one embodiment, the antisense oligomer is an oligonucleotide that is sufficiently complementary to an Ect2 mRNA to bind to and prevent translation from the Ect2 mRNA, preferably by binding to the 5' untranslated region. Ect2-specific antisense oligonucleotides preferably range from at least 6 to about 200 nucleotides. In some embodiments the oligonucleotide is preferably at least 10, 15, or 20 nucleotides in length. In other embodiments, the oligonucleotide is preferably less than 50, 40, or 30 nucleotides in length. The oligonucleotide can be DNA or RNA, a chimeric mixture of DNA and RNA, derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone. The oligonucleotide may include other appending groups such as peptides, agents that facilitate transport across the cell membrane, hybridization-triggered cleavage agents, and intercalating agents.

[0051] In another embodiment, the antisense oligomer is a phosphorothioate morpholino oligomer (PMO). PMOs are assembled from four different morpholino subunits, each of which containing one of four genetic bases (A, C, G, or T) linked to a six-membered morpholine ring. Polymers of these subunits are joined by non-ionic phosphodiarnidate inter-subunit linkages. Methods of producing and using PMOs and other antisense oligonucleotides are well known in the art (e.g. see WO99/18193; Summerton J, and Weller D, *Antisense Nucleic Acid Drug Dev* 1997, 7:187-95; Probst JC, *Methods* (2000) 22:271-281; U.S. Pat Nos. 5,325,033 and 5,378,841).

[0052] Antisense oligomers are commonly used as research reagents, diagnostics, and therapeutics. For example, antisense oligonucleotides, which are able to specifically inhibit gene expression, are often used to elucidate the function of particular genes (see, e.g., U.S. Pat. No. 6,165,790). Antisense oligomers are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense oligomers have been employed as therapeutic moieties in the treatment of disease states in animals and humans and have been demonstrated in numerous clinical trials to be safe and effective (Milligan JF, *et al*, *Current Concepts in Antisense Drug Design*, *J Med Chem.* (1993) 36:1923-1937; Tonkinson JL *et al.*, *Antisense Oligodeoxynucleotides as Clinical Therapeutic Agents*, *Cancer Invest.* (1996) 14:54-65). Accordingly, in one aspect of the invention, an Ect2-specific antisense oligomer is used in an assay to further elucidate the function of Ect2 in the p21 pathway. In another aspect of the invention, an Ect2-specific antisense oligomer is used as a therapeutic agent for treatment of metabolic pathologies.

- [0053] Alternative preferred Ect2-modulating agents are double-stranded RNA species mediating RNA interference (RNAi). RNAi is the process of sequence-specific, post-transcriptional gene silencing in animals and plants, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the silenced gene. Methods relating to the use of RNAi to silence genes in *C. elegans*, *Drosophila*, plants, and mammals are known in the art (Fire A, et al., 1998 Nature 391:806-811; Fire, A. Trends Genet. 15, 358-363 (1999); Sharp, P. A. RNA interference 2001. Genes Dev. 15, 485-490 (2001); Hammond, S. M., et al., Nature Rev. Genet. 2, 110-1119 (2001); Tuschl, T. Chem. Biochem. 2, 239-245 (2001); Hamilton, A. et al., Science 286, 950-952 (1999); Hammond, S. M., et al., Nature 404, 293-296 (2000); Zamore, P. D., et al., Cell 101, 25-33 (2000); Bernstein, E., et al., Nature 409, 363-366 (2001); Elbashir, S. M., et al., Genes Dev. 15, 188-200 (2001); WO0129058; WO9932619, and Elbashir SM, et al., 2001 Nature 411:494-498).

Assay Systems

- [0054] The invention provides assay systems for identifying specific modulators of Ect2 activity. In general, primary assays are used to identify or confirm a modulator's specific biochemical or molecular effect with respect to the Ect2 nucleic acid or protein. In general, secondary assays further assess the activity of an Ect2-modulating agent identified by a primary assay and may confirm that the modulating agent affects Ect2 in a manner relevant to the p21 pathway and cell cycle regulation.

Primary Assays

- [0055] The type of modulator tested generally determines the type of primary assay.
- [0056] For small molecule modulators, screening assays are used to identify candidate modulators. Screening assays may be cell-based or may use a cell-free system that recreates or retains the relevant biochemical reaction of the target protein (reviewed in Sittampalam GS *et al.*, Curr Opin Chem Biol (1997) 1:384-91 and accompanying references). As used herein the term "cell-based" refers to assays using live cells, dead cells, or a particular cellular fraction, such as a membrane, endoplasmic reticulum, or mitochondrial fraction. Cell-based screening assays usually require systems for recombinant expression of Ect2 and any auxiliary proteins demanded by the particular assay. The term "cell free" encompasses assays using substantially purified protein (either endogenous or recombinantly produced), partially purified cellular extracts, or

crude cellular extracts. Screening assays may detect a variety of molecular events, including protein-DNA interactions, protein-protein interactions (*e.g.*, receptor-ligand binding), transcriptional activity (*e.g.*, using a reporter gene), enzymatic activity (*e.g.*, via a property of the substrate), activity of second messengers, immunogenicity and changes in cellular morphology or other cellular characteristics. Appropriate screening assays may use a wide range of detection methods including fluorescent (Klebe C, et al., *Biochemistry* (1995) 34:12543-12552), radioactive (Hart M, et al., *Nature* (1991) 354:311-314), colorimetric, spectrophotometric, and amperometric methods, to provide a read-out for the particular molecular event detected, often in high throughput screening (HTS) formats (for example, see Hertzberg RP, and Pope AJ, *Current Opinion in Chemical Biology* (2000) 4:445-451).

[0057] Assays for binding agents include screens for compounds that modulate Ect2 interaction with a natural Ect2 binding target. The Ect2 polypeptide used in such assays may be fused to another polypeptide such as a peptide tag for detection or anchoring, etc. In a particular embodiment, the binding target is RhoA, RhoC, Rac, or Cdc42, or portion thereof that provides binding affinity and avidity to the subject Ect2 polypeptide conveniently measurable in the assay and preferably comparable to the intact RhoA, RhoC, Rac, or Cdc42. The Ect2 and binding target are incubated in the presence and absence (*i.e.* control) of a candidate Ect2 modulating agent under conditions whereby, but for the presence of the candidate modulating agent, the Ect2 polypeptide specifically binds the cellular binding target, portion or analog with a reference binding affinity. After incubation, the agent-biased binding between the Ect2 polypeptide and one or more binding targets is detected by any of a variety of methods depending on the nature of the product and other assay components, such as through optical or electron density, radiative emissions, nonradiative energy transfers, etc. or indirect detection with antibody conjugates, etc. A difference in the binding affinity of Ect2 to the target in the absence of the agent, as compared with the binding affinity in the presence of the agent indicates that the agent modulates the binding of the Ect2 to the Ect2 binding target. A difference, as used herein, is statistically significant and preferably represents at least a 50%, preferably at least 60%, more preferably 75%, and most preferably a 90% difference.

[0058] We developed a solid-phase radiometric high throughput assay format to measure activity of Ect2, and other GEFs. The GTPase/GEF activity is evaluated by measuring the binding of the activating ligand -GTP in solid phase. In this assay, the GTPase

(such as Rho or Rac) is adsorbed to the bottom of commercially available plates, such as Flashplate (Perkin Elmer Life Sciences), which have scintillant coated on the bottom and sides of the wells. The plates are then washed to remove excess protein. A test compound (candidate modulating agent) is added, followed by GEF (such as Ect2, or a functional Ect2 fragment such as a fragment comprising the Dbp homology domain), followed by ³⁵S labeled GTP. When the radioisotope is associated with the solid phase it is measured in a scintillation counter just as if liquid scintillant had been added. Thus, following incubation, the plates are simply counted without further processing, since only ³⁵S-GTP that is exchanged onto the GTPase will be detected. Unbound radioactive GTP remains in solution and is undetectable. Magnesium chloride is used as a negative control. In the absence of GEF, 2mM MgCl₂ prevents GTP from binding, and thus, reduces the number of cpm/well. Inclusion of GEF in the assay will rescue the MgCl₂ inhibited exchange.

[0059] Other preferred assay formats use fluorescence technologies, including fluorescence polarization, time-resolved fluorescence, and fluorescence resonance energy transfer. These systems offer means to monitor protein-protein or DNA-protein interactions in which the intensity of the signal emitted from dye-labeled molecules depends upon their interactions with partner molecules (*e.g.*, Selvin PR, Nat Struct Biol (2000) 7:730-4; Fernandes PB, Curr Opin Chem Biol (1998) 2:597-603; Hertzberg RP and Pope AJ, Curr Opin Chem Biol (2000) 4:445-451). We developed an FMAT (Fluorescent Microvolume Assay Technology) assay format to measure the protein-protein interaction of a GEF and GTPase, whereby GST-fused GTPase (such as RhoA, RhoC, or Rac) is attached to polystyrene beads and the GEF (such as Ect2) is labeled with Cy5 (a long wavelength fluorophore, available from Amersham). When the GTPase and the GEF are associated, there is an increase in fluorescence associated with GTPase beads, which settle to the bottom of the well and are detected using an FMAT 8100 HTS system (Applied Biosystems). Potential inhibitors interfere with the GEF-GTPase association with subsequent decrease in fluorescence.

[0060] For antibody modulators, appropriate primary assays test the antibody's specificity for and affinity to the Ect2 protein. Methods for testing antibody specificity and affinity are well known in the art. Alternatively or additionally, primary assays for antibody modulators may comprise the screening assays described above, used to detect the Ect2 modulator's specific activity.

[0061] For nucleic acid modulators, primary assays may test the ability of the nucleic acid modulator to inhibit Ect2 mRNA or protein expression. In general, expression analysis comprises comparing Ect2 expression in like populations of cells (*e.g.*, two pools of cells that endogenously or recombinantly express Ect2) in the presence and absence of the nucleic acid modulator. Methods for analyzing mRNA and protein expression are well known in the art. For instance, Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR (*e.g.*, using the TaqMan®, PE Applied Biosystems), or microarray analysis may be used to confirm that Ect2 mRNA expression is reduced in cells treated with the nucleic acid modulator (*e.g.*, Current Protocols in Molecular Biology (1994) Ausubel FM *et al.*, eds., John Wiley & Sons, Inc., chapter 4; Freeman WM *et al.*, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; Blohm DH and Guiseppi-Elie, ACurr Opin Biotechnol 2001, 12:41-47). Proteins are most commonly detected with specific antibodies or antisera directed against either the Ect2 protein or specific peptides. Protein expression can be monitored using by a variety of means including Western blotting, the enzyme-linked immunosorbent assay (ELISA), or in situ detection (Harlow E and Lane D (eds.) Using Antibodies: A Laboratory Manual, 1999, Cold Spring Harbor Laboratory Press, New York).

Secondary assays

[0062] Secondary validation can use essentially the same assays used to functionally validate the participation of an ect2 gene in a p21 related pathway. Whereas the afore-described functional validation assays generally compare cells expressing altered levels of an Ect2 protein, secondary validation assays generally compare like populations of cells (*e.g.*, two pools of wild type cells) in the presence and absence of the candidate modulator.

[0063] In another embodiment, secondary validation may use the same assays used for high throughput screening. These methods can confirm the activity of a modulator not identified through high throughput screening, such as an antibody or an antisense oligonucleotide modulator, or can confirm the activity of a small molecule modulator identified using a different high throughput screening assay. These assays may also be used to confirm the specificity of a candidate modulator.

[0064] Additionally, the modulator is assayed for its effectiveness on the Ect2 in a p21 related manner. Such assays include cell cycle, apoptosis, proliferation, and hypoxic

induction assays, among others, as described above. To assess the role of modulators, these assays are performed in presence or absence of the modulator in p21 normal and p21 mutated backgrounds. These assays may use cell lines deficient in p21 such as HCT116 colon cancer cells, among others, available from ATCC (American Type Culture Collection, Manassas, VA).

Therapeutic and diagnostic applications

- [0065] When used for anti-tumor therapy in a patient, Ect2 modulating agents are administered to the patient in therapeutically effective amounts that eliminate or reduce the patient's tumor burden. They will normally be administered parenterally, when possible at the target cell site, or intravenously. The dose and dosage regimen will depend upon the nature of the cancer (primary or metastatic), its population, the target site, the characteristics of the particular immunotoxin (when used), e.g., its therapeutic index, whether the agent is administered in combination with other therapeutic agents, and the patient's history. The amount of agent administered will typically be in the range of approximately 0.1 - 10 mg/kg of patient weight.
- [0066] For parenteral administration, the agents will be formulated in a unit dosage injectable or inhalable (solution, suspension, emulsion) form in association with a pharmaceutically acceptable vehicle, typically in a concentration of about 1 - 10 mg/ml.
- [0067] Antibodies that specifically bind Ect2 may be used for the diagnosis of conditions or diseases characterized by expression of Ect2, or in assays to monitor patients being treated with Ect2 modulating agents. Diagnostic assays for Ect2 include methods which utilize the antibody and a label to detect Ect2 in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by joining them, either covalently or non-covalently, with a reporter molecule.
- [0068] Diagnosis of conditions characterized by expression of Ect2 may also be accomplished by any of a variety of methods such as Northern or TaqMan® analysis (discussed *supra*) to measure expression of Ect2 in patient samples.
- [0069] The following experimental section and examples are offered by way of illustration and not by way of limitation.

EXAMPLES

I. High throughput fluorescent or radioactive homogeneous assay

[0070] Various combinations of fluorescently (with N-Methylanthraniloyl, Bodipy or other commonly used fluorophores) or radioactively (^3H , ^{35}S , or ^{33}P) labeled GTP, GDP, dGTP, or dGTP and ect2 are added to each well of a 96-well plate, along with a test compound of choice. Fluorescent measurements (of over 500nm to reduce background fluorescence) or radioactivity measurements indicative of the exchange reaction are then taken.

[0071] The above assay may be performed where all components are in solution, or alternatively, where at least one component is attached to beads that are 10nm or larger in diameter (such as SPA beads from Amersham, Alpha screen beads from Packard, or FMAT beads from PE Biosystems).

II. High throughput Elisa format assay

[0072] Various combinations of Glutathione-S-transferase/ RhoA, Rhoc, RAC, or CDC42 polypeptide fusion protein and biotinylated Ect2 are added to each well of a microtiter plate (Reacti-Bind Streptavidin-Coated, White Polystyrene Plates (#15118B), which have been blocked by Super-Blocking Reagent from Pierce) in assay buffer (0.01M HEPES, 0.15M NaCl, 0.002M MgCl_2). Test compounds are then added to each well, and incubated at room temperature for 1 hour. Anti-GST, rabbit and anti-rabbit antibodies are then added to each well and incubated on ice for 1 hour. Plates are then washed with water, diluted Supersignal substrate is added to each well, and chemiluminescence is then measured.

III. Solid Phase Rac1-dbl screen

[0073] 3 x 30 plates/day

Day 1

Reconstitute 4x10mg GST-Rac1 in 4x10ml Assay Buffer

Prepare 3L Assay Buffer (to 1L 1.4mM Tris pH7.5, 5mM MgCl_2 , 0.3% sucrose, 0.1% dextran add 1ml 1M DTT/L)

Dilute GST-Rac1 into 100ml Assay Buffer

Mix

Dilute into 1L Assay Buffer

Mix

Dilute into 2L Assay Buffer.

Giving a final volume of 2L of 10ug/ml GST-Rac1 in Assay Buffer.

Coat 90 Flashplates (Perkin Elmer Life Sciences) with 0.5ug/well GST-Rac1
(50ul of 10ug/ml GST-cdc42 in Assay Buffer)

Place at 4°C overnight

Prepare 2L TBS (50mM Tris-HCl, pH 7.4, 150 mM NaCl).

Day 2.

Thaw 1 vial (1mCi) [³⁵S]GTPγS.

Wash 30 GST-cdc42 coated plates 3x70ul TBS

Dilute compound in plates by addition of 10ul Assay Buffer

Transfer 5ul compound dilution to assay plates

Prepare 0.1L of Assay buffer containing 1mCi [³⁵S]GTPγS, 500nM Dbl

Add 5ul/well dbl/GTPγS (columns 1&2 receive buffer alone)

Seal

Incubate @ room temp x 1 hour

Count in the Trilux Scintillation counter

Prepare the remaining 2x30 plates as described above and store at room temp.

IV. FMAT GEF assay

[0074] 0.5ml Protein G polystyrene beads (7u, 0.5% w/v Spherotech [Libertyville, IL]) are washed three times with PBS and resuspended in 0.5ml PBS. For monitoring of biomolecular binding events, Anti-GST (0.25ug BIAcore [Uppsala, Sweden]) is added and incubated at room temperature for 30minutes. The beads are then washed three times with PBS and resuspended in 0.5ml PBS. The sample is split into 2x0.25ml aliquots and 2.5ug of either GST or GST-RhoA is added and incubated at room temperature for 30 minutes. The beads are then washed three times with PBS and resuspended in 0.25ml PBS.

[0075] (His)6 tagged Ect2-dbl domain is labeled with Cy 5 using a Cy5 monoclonal antibody labeling kit according to the manufacturers instruction (Amersham).

[0076] To 400ul of PBS add 4ul of either "RhoA-beads" or "GST-beads" giving a final concentration of 20nM RhoA or GST. Add 200nM Cy5-Ect2_dbl. Mix and aliquot 8x50ul into a 96 well FMAT plate. Incubate at room temperature for 1 hour and read in the Cy5 detecting channel of an FMAT 8100 HTS system.

[0077] All references cited herein, including sequence information in referenced Genbank identifier numbers and website references, are incorporated herein in their entireties.

WHAT IS CLAIMED IS

1. A purified ECT2 polypeptide having GEF activity and comprising an amino acid sequence having at least 95% sequence identity with SEQ ID NO:2 or SEQ ID NO:4.
2. A purified ECT2 polypeptide having GEF activity and comprising an amino acid sequence having at least 234 contiguous amino acid residues of either SEQ ID NO:2 or SEQ ID NO:4.
3. A recombinant expression system comprising a DNA or RNA molecule, wherein said expression system produces an Ect2 polypeptide having GEF activity and comprising an amino acid sequence having at least 95% sequence identity with SEQ ID NO:2 or SEQ ID NO:4 when said expression system is present in a compatible host cell.
4. A host cell comprising the expression system of claim 3.
5. A process for producing an Ect2 polypeptide comprising culturing the host cell of Claim 4 under conditions suitable for expression of said Ect2 protein and recovering said protein.
6. A process for producing a cell which produces an Ect2 polypeptide comprising the transformation or transfection of a host cell with the expression system of claim 3 such that the host cell, under appropriate culture conditions, produces an Ect2 polypeptide.
7. A method of screening for agents that modulate the interaction of the Ect2 polypeptide of claim 1 or 2 with an Ect2 binding target, comprising incubating the Ect2 polypeptide and said binding target with a candidate agent under conditions conducive for binding and determining whether said candidate agent modulates the binding of the Ect2 polypeptide with the Ect2 binding target.

8. The method of claim 7, wherein said binding target is a natural intracellular substrate, and said modulation of the binding of the Ect2 polypeptide with the Ect2 binding target is detected as GDP/GTP exchange of said substrate.
9. The method of claim 7, wherein binding of Ect2 polypeptide and binding target in presence of said candidate agent is detected in solid phase.
10. The method of claim 7 wherein said binding target is selected from the group consisting of RhoA, RhoC, Rac, CDC42.
11. The method of claim 7 wherein said agent is an antibody.
12. The method of claim 7 wherein said agent is a small organic molecule.
13. The method of claim 7 wherein said agent is an antisense oligomer.

SEQUENCE LISTING

<110> Exelixis, Inc.

<120> Human ect2 sequences and methods of use

<130> ect2utility

<150> US 60/239,689

<151> 2000-10-12

<160> 4

<170> PatentIn version 3.0

<210> 1

<211> 2652

<212> DNA

<213> Homo sapiens

<400> 1

atggctgaaa atagtgtatt aacatccact actgggagga ctagcttggc agactcttcc	60
atcttttgatt ctaaagttac tgagatttcc aaggaaaact tacttattgg atctacttca	120
tatgtagaag aagagatgcc tcagattgaa acaagagtga tattggttca agaagctgga	180
aaacaagaag aacttataaa agccttaaag gacattaaag tgggctttgt aaagatggag	240
tcagtggaag aatttgaagg tttggattct ccggaatttg aaaatgtatt tgtagtcacg	300
gactttcagg attctgtctt taatgacctc tacaaggctg attgtagagt tattggacca	360
ccagttgtat taaattgttc acaaaaagga gagcctttgc cattttcatg tcgccggtg	420
tattgtacaa gtatgatgaa tctagtacta tgctttactg gatttaggaa aaaagaagaa	480
ctagtcaggt tgggtgacatt ggtccatcac atgggtggag ttattcgaaa agactttaat	540
tcaaaagtta cacatttggg ggcaaattgt acacaaggag aaaaattcag ggttgctgtg	600
agtctaggta ctccaattat gaagccagaa tggatttata aagcttggga aaggcggaat	660
gaacaggatt tctatgcagc agttgatgac tttagaaatg aatttaaagt tcctccattt	720
caagattgta ttttaagttt cctgggattt tcagatgaag agaaaacaa tatggaagaa	780
atgactgaaa tgcaaggagg taaatattta ccgcttggag atgaaagatg cactcacctt	840
gtagttgaag agaatatagt aaaagatcct ccctttgaac cttcaaagaa actttatggt	900
gtcaagcaag agtggttctg gggaagcatt caaatggatg cccgagctgg agaaactatg	960
tatttatatg aaaaggcaaa tactcctgag ctcaagaaat cagtgtcaat gctttctcta	1020
aataccccta acagcaatcg caaacgacgt cgtttaaaag aacacttgc tcagctttca	1080
agagagacag acgtgtcacc atttccaccc cgtaagcgcc catcagctga gcactccctt	1140
tccatagggt cactcctaga tatctccaac acaccagagt ctagcattaa ctatggagac	1200
accccaaagt cttgtactaa gtcttctaaa agctccactc cagttccttc aaagcagtca	1260

gcaagggtggc aagttgcaaa agagctttat caaactgaaa gtaattatgt taatatattg 1320
 gcaacaatta ttcagttatt tcaagtacca ttggaagagg aaggacaacg tgggtggacct 1380
 atccttgcac cagaggagat taagactatt tttggttagc tcccagatat ctttgatgta 1440
 cacactaaga taaaggatga tcttgaagac cttatagtta attgggatga gagcaaaaagc 1500
 attggtgaca tttttctgaa atattcaaaa gatttggtta aaacctaccc tccctttgta 1560
 aacttctttg aaatgagcaa ggaacaatt attaaatgtg aaaaacagaa accaagattt 1620
 catgcttttc tcaagataaa ccaagcaaaa ccagaatgtg gacggcagag ccttggtgaa 1680
 cttcttatcc gaccagtaca gaggttacct agtggtgcat tactttttaa tgatcttaag 1740
 aagcatacag ctgatgaaaa tccagacaaa agcacttttag aaaaagctat tggatcactg 1800
 aaggaagtaa tgacgcatat taatgaggat aagagaaaaa cagaagctca aaagcaaatt 1860
 tttgatgttg tttatgaagt agatggatgc ccagctaate ttttatcttc tcaccgaagc 1920
 ttagtacagc gggttgaaac aatttctcta ggtgagcacc cctgtgacag aggagaacaa 1980
 gtaactctct tcctcttcaa tgattgccta gagatagcaa gaaaacggca caaggttatt 2040
 ggcactttta ggagtctca tggccaaacc cgacccccag cttctcttaa gcatattcac 2100
 ctaatgcctc tttctcagat taagaaggta ttggacataa gagagacaga agattgccat 2160
 aatgcttttg ccttgcttgt gaggccacca acagagcagg caaatgtgct actcagtttc 2220
 cagatgacat cagatgaact tccaaaagaa aactggctaa agatgctgtg tgcacatgta 2280
 gctaacacca tttgtaaagc agatgctgag aatcttattt atactgctga tccagaatcc 2340
 tttgaagtaa atacaaaaga tatggacagt acattgagta gagcatcaag agcaataaaa 2400
 aagacttcaa aaaagggtac aagagcatte tctttctcca aaactccaaa aagagctctt 2460
 cgaagggtc ttatgacatc ccacgggtca gtggaggga gaagtccttc cagcaatgat 2520
 aagcatgtaa tgagtgtct tcttagcaca tcatcattag caggtatccc ttctccctcc 2580
 cttgtcagcc ttccttctct ctttgaaagg agaagtcata cgttaagtag atctacaact 2640
 catttgatat ga 2652

<210> 2
 <211> 883
 <212> PRT
 <213> Homo sapiens

<400> 2

Met Ala Glu Asn Ser Val Leu Thr Ser Thr Thr Gly Arg Thr Ser Leu
 1 5 10 15

Ala Asp Ser Ser Ile Phe Asp Ser Lys Val Thr Glu Ile Ser Lys Glu
 20 25 30

Asn Leu Leu Ile Gly Ser Thr Ser Tyr Val Glu Glu Glu Met Pro Gln
 35 40 45
 Ile Glu Thr Arg Val Ile Leu Val Gln Glu Ala Gly Lys Gln Glu Glu
 50 55 60
 Leu Ile Lys Ala Leu Lys Asp Ile Lys Val Gly Phe Val Lys Met Glu
 65 70 75 80
 Ser Val Glu Glu Phe Glu Gly Leu Asp Ser Pro Glu Phe Glu Asn Val
 85 90 95
 Phe Val Val Thr Asp Phe Gln Asp Ser Val Phe Asn Asp Leu Tyr Lys
 100 105 110
 Ala Asp Cys Arg Val Ile Gly Pro Pro Val Val Leu Asn Cys Ser Gln
 115 120 125
 Lys Gly Glu Pro Leu Pro Phe Ser Cys Arg Pro Leu Tyr Cys Thr Ser
 130 135 140
 Met Met Asn Leu Val Leu Cys Phe Thr Gly Phe Arg Lys Lys Glu Glu
 145 150 155 160
 Leu Val Arg Leu Val Thr Leu Val His His Met Gly Gly Val Ile Arg
 165 170 175
 Lys Asp Phe Asn Ser Lys Val Thr His Leu Val Ala Asn Cys Thr Gln
 180 185 190
 Gly Glu Lys Phe Arg Val Ala Val Ser Leu Gly Thr Pro Ile Met Lys
 195 200 205
 Pro Glu Trp Ile Tyr Lys Ala Trp Glu Arg Arg Asn Glu Gln Asp Phe
 210 215 220
 Tyr Ala Ala Val Asp Asp Phe Arg Asn Glu Phe Lys Val Pro Pro Phe
 225 230 235 240
 Gln Asp Cys Ile Leu Ser Phe Leu Gly Phe Ser Asp Glu Glu Lys Thr
 245 250 255
 Asn Met Glu Glu Met Thr Glu Met Gln Gly Gly Lys Tyr Leu Pro Leu
 260 265 270
 Gly Asp Glu Arg Cys Thr His Leu Val Val Glu Glu Asn Ile Val Lys
 275 280 285
 Asp Leu Pro Phe Glu Pro Ser Lys Lys Leu Tyr Val Val Lys Gln Glu
 290 295 300
 Trp Phe Trp Gly Ser Ile Gln Met Asp Ala Arg Ala Gly Glu Thr Met
 305 310 315 320
 Tyr Leu Tyr Glu Lys Ala Asn Thr Pro Glu Leu Lys Lys Ser Val Ser
 325 330 335
 Met Leu Ser Leu Asn Thr Pro Asn Ser Asn Arg Lys Arg Arg Arg Leu
 340 345 350
 Lys Glu Thr Leu Ala Gln Leu Ser Arg Glu Thr Asp Val Ser Pro Phe

355	360	365
Pro Pro Arg Lys Arg Pro Ser Ala Glu His Ser Leu Ser Ile Gly Ser		
370	375	380
Leu Leu Asp Ile Ser Asn Thr Pro Glu Ser Ser Ile Asn Tyr Gly Asp		
385	390	395
Thr Pro Lys Ser Cys Thr Lys Ser Ser Lys Ser Ser Thr Pro Val Pro		
	405	410
		415
Ser Lys Gln Ser Ala Arg Trp Gln Val Ala Lys Glu Leu Tyr Gln Thr		
	420	425
		430
Glu Ser Asn Tyr Val Asn Ile Leu Ala Thr Ile Ile Gln Leu Phe Gln		
	435	440
		445
Val Pro Leu Glu Glu Glu Gly Gln Arg Gly Gly Pro Ile Leu Ala Pro		
	450	455
		460
Glu Glu Ile Lys Thr Ile Phe Gly Ser Ile Pro Asp Ile Phe Asp Val		
	465	470
		475
His Thr Lys Ile Lys Asp Asp Leu Glu Asp Leu Ile Val Asn Trp Asp		
	485	490
		495
Glu Ser Lys Ser Ile Gly Asp Ile Phe Leu Lys Tyr Ser Lys Asp Leu		
	500	505
		510
Val Lys Thr Tyr Pro Pro Phe Val Asn Phe Phe Glu Met Ser Lys Glu		
	515	520
		525
Thr Ile Ile Lys Cys Glu Lys Gln Lys Pro Arg Phe His Ala Phe Leu		
	530	535
		540
Lys Ile Asn Gln Ala Lys Pro Glu Cys Gly Arg Gln Ser Leu Val Glu		
	545	550
		555
Leu Leu Ile Arg Pro Val Gln Arg Leu Pro Ser Val Ala Leu Leu Leu		
	565	570
		575
Asn Asp Leu Lys Lys His Thr Ala Asp Glu Asn Pro Asp Lys Ser Thr		
	580	585
		590
Leu Glu Lys Ala Ile Gly Ser Leu Lys Glu Val Met Thr His Ile Asn		
	595	600
		605
Glu Asp Lys Arg Lys Thr Glu Ala Gln Lys Gln Ile Phe Asp Val Val		
	610	615
		620
Tyr Glu Val Asp Gly Cys Pro Ala Asn Leu Leu Ser Ser His Arg Ser		
	625	630
		635
Leu Val Gln Arg Val Glu Thr Ile Ser Leu Gly Glu His Pro Cys Asp		
	645	650
		655
Arg Gly Glu Gln Val Thr Leu Phe Leu Phe Asn Asp Cys Leu Glu Ile		
	660	665
		670
Ala Arg Lys Arg His Lys Val Ile Gly Thr Phe Arg Ser Pro His Gly		
	675	680
		685

Gln Thr Arg Pro Pro Ala Ser Leu Lys His Ile His Leu Met Pro Leu
 690 695 700
 Ser Gln Ile Lys Lys Val Leu Asp Ile Arg Glu Thr Glu Asp Cys His
 705 710 715 720
 Asn Ala Phe Ala Leu Leu Val Arg Pro Pro Thr Glu Gln Ala Asn Val
 725 730 735
 Leu Leu Ser Phe Gln Met Thr Ser Asp Glu Leu Pro Lys Glu Asn Trp
 740 745 750
 Leu Lys Met Leu Cys Arg His Val Ala Asn Thr Ile Cys Lys Ala Asp
 755 760 765
 Ala Glu Asn Leu Ile Tyr Thr Ala Asp Pro Glu Ser Phe Glu Val Asn
 770 775 780
 Thr Lys Asp Met Asp Ser Thr Leu Ser Arg Ala Ser Arg Ala Ile Lys
 785 790 795 800
 Lys Thr Ser Lys Lys Val Thr Arg Ala Phe Ser Phe Ser Lys Thr Pro
 805 810 815
 Lys Arg Ala Leu Arg Arg Ala Leu Met Thr Ser His Gly Ser Val Glu
 820 825 830
 Gly Arg Ser Pro Ser Ser Asn Asp Lys His Val Met Ser Arg Leu Ser
 835 840 845
 Ser Thr Ser Ser Leu Ala Gly Ile Pro Ser Pro Ser Leu Val Ser Leu
 850 855 860
 Pro Ser Phe Phe Glu Arg Arg Ser His Thr Leu Ser Arg Ser Thr Thr
 865 870 875 880
 His Leu Ile

<210> 3
 <211> 2745
 <212> DNA
 <213> Homo sapiens

<400> 3
 atggctgaaa atagtgtatt aacatccact actgggagga ctagcttggc agactcttcc 60
 atttttgatt cttaaagttac tgagatttcc aaggaaaact tacttattgg atctacttca 120
 tatgtagaag aagagatgcc tcagattgaa acaagagtga tattggttca agaagctgga 180
 aaacaagaag aacttataaa agccttaaag actattaaaa taatggaagt ccctgttata 240
 aagataaaag aaagttgtcc tggaaaatcg gatgaaaaat taataaaaag tgttattaat 300
 atggacatta aagtgggctt tgtaaagatg gagtcagtgg aagaatttga aggtttggat 360
 tctccggaat ttgaaaatgt atttgtagtc acggactttc aggattctgt ctttaatgac 420
 ctctacaagg ctgattgtag agttatttga ccaccagttg tattaaattg ttcacaaaaa 480
 ggagagcctt tgccattttc atgtcgcccg ttgtatttga caagtatgat gaatctagta 540

ctatgcttta ctggatttag gaaaaaagaa gaactagtca ggttggtgac attggtccat	600
cacatgggtg gagttattcg aaaagacttt aattcaaaag ttacacattt ggtggcaaat	660
tgtacacaag gagaaaaatt cagggttgct gtgagtctag gtactccaat tatgaagcca	720
gaatggattt ataaagcttg ggaaaggcgg aatgaacagg atttctatgc agcagttgat	780
gacttttagaa atgaatttaa agttcctcca ttccaagatt gtattttaag ttctctggga	840
ttttcagatg aagagaaaac caatatggaa gaaatgactg aaatgcaagg aggtaaatat	900
ttaccgcttg gaaatgaaag atgcactcac cttgtagttg aagagaatat agtaaaagat	960
cttccctttg aaccttcaaa gaaactttat gttgtcaagc aagagtgggt ctggggaagc	1020
attcaaatgg atgcccagac tggagaaact atgtatttat atgaaaaggc aaatactcct	1080
gagctcaaga aatcagtgtc aatgctttct ctaaataccc ctaacagcaa tcgcaaacga	1140
cgtcgtttta aagaaacact tgctcagctt tcaagagaga cagacgtgac accatttcca	1200
ccccgtaagc gcccatcagc tgagcactcc ctttccatag ggtcactcct agatatctcc	1260
aacacaccag agtctagcat taactatgga gacaccccaa agtcttgtac taagtcttct	1320
aaaagctcca ctccagttcc ttcaaagcag tcagcaaggt ggcaagttgc aaaagagctt	1380
tatcaaactg aaagtaatta tgttaatata ttggcaacaa ttattcagtt atttcaagta	1440
ccatttgaag aggaaggaca acgtgggtga cctatccttg caccagagga gattaagact	1500
attttttgga gcatcccaga tatctttgat gtacacacta agataaagga tgatcttgaa	1560
gaccttatag ttaattggga tgagagcaaa agcatfgtg acatttttct gaaatattca	1620
aaagatttgg taaaaaccta cctcccttt gttaaacttct ttgaaatgag caaggaaaca	1680
attattaaat gtgaaaaaca gaaaccaaga ttcatgctt ttctcaagat aaaccaagca	1740
aaaccagaat gtggacggca gagccttggt gaacttctta tccgaccagt acagaggtta	1800
cccagtggtg cattactttt aaatgatctt aagaagcata cagctgatga aaatccagac	1860
aaaagcactt tagaaaaagc tattggatca ctgaaggaag taatgacgca tattaatgag	1920
gataagagaa aaacagaagc tcaaaagcaa atttttgatg ttgtttatga agtagatgga	1980
tgcccagcta atcttttata ttctcacga agcttagtac agcgggttga aacaatttct	2040
ctaggtgagc acccctgtga cagaggagaa caagtaactc tcttctctt caatgattgc	2100
ctagagatag caagaaaacg gcacaaggtt attggcactt ttaggagtc tcatggccaa	2160
accgacccc cagcttctct taagcatatt cacctaagtc ctctttctca gattaagaag	2220
gtatttgaca taagagagac agaagattgc cataatgctt ttgccttgct tgtgaggcca	2280
ccaacagagc aggcaaatgt gctactcagt ttccagatga catcagatga acttccaaaa	2340
gaaaactggc taaagatgct gtgtcgacat gtagctaaca ccatttgtaa agcagatgct	2400

gagaatctta ttatactgc tgatccagaa tcctttgaag taaatacaaa agatatggac 2460
 agtacattga gtagagcatc aagagcaata aaaaagactt caaaaaaggt tacaagagca 2520
 ttctctttct ccaaaactcc aaaaagagct ctctgaaggg ctcttatgac atcccacggc 2580
 tcagtggagg gaagaagtcc ttccagcaat gataagcatg taatgagtcg tctttctagc 2640
 acatcatcat tagcaggtat cctttctccc tccctgtca gccttccttc cttctttgaa 2700
 aggagaagtc atacgttaag tagatctaca actcatttga tatga 2745

<210> 4
 <211> 914
 <212> PRT
 <213> Homo sapiens

<400> 4

Met Ala Glu Asn Ser Val Leu Thr Ser Thr Thr Gly Arg Thr Ser Leu
 1 5 10 15
 Ala Asp Ser Ser Ile Phe Asp Ser Lys Val Thr Glu Ile Ser Lys Glu
 20 25 30
 Asn Leu Leu Ile Gly Ser Thr Ser Tyr Val Glu Glu Glu Met Pro Gln
 35 40 45
 Ile Glu Thr Arg Val Ile Leu Val Gln Glu Ala Gly Lys Gln Glu Glu
 50 55 60
 Leu Ile Lys Ala Leu Lys Thr Ile Lys Ile Met Glu Val Pro Val Ile
 65 70 75 80
 Lys Ile Lys Glu Ser Cys Pro Gly Lys Ser Asp Glu Lys Leu Ile Lys
 85 90 95
 Ser Val Ile Asn Met Asp Ile Lys Val Gly Phe Val Lys Met Glu Ser
 100 105 110
 Val Glu Glu Phe Glu Gly Leu Asp Ser Pro Glu Phe Glu Asn Val Phe
 115 120 125
 Val Val Thr Asp Phe Gln Asp Ser Val Phe Asn Asp Leu Tyr Lys Ala
 130 135 140
 Asp Cys Arg Val Ile Gly Pro Pro Val Val Leu Asn Cys Ser Gln Lys
 145 150 155 160
 Gly Glu Pro Leu Pro Phe Ser Cys Arg Pro Leu Tyr Cys Thr Ser Met
 165 170 175
 Met Asn Leu Val Leu Cys Phe Thr Gly Phe Arg Lys Lys Glu Glu Leu
 180 185 190
 Val Arg Leu Val Thr Leu Val His His Met Gly Gly Val Ile Arg Lys
 195 200 205
 Asp Phe Asn Ser Lys Val Thr His Leu Val Ala Asn Cys Thr Gln Gly
 210 215 220

Glu Lys Phe Arg Val Ala Val Ser Leu Gly Thr Pro Ile Met Lys Pro
 225 230 235 240
 Glu Trp Ile Tyr Lys Ala Trp Glu Arg Arg Asn Glu Gln Asp Phe Tyr
 245 250 255
 Ala Ala Val Asp Asp Phe Arg Asn Glu Phe Lys Val Pro Pro Phe Gln
 260 265 270
 Asp Cys Ile Leu Ser Phe Leu Gly Phe Ser Asp Glu Glu Lys Thr Asn
 275 280 285
 Met Glu Glu Met Thr Glu Met Gln Gly Gly Lys Tyr Leu Pro Leu Gly
 290 295 300
 Asp Glu Arg Cys Thr His Leu Val Val Glu Glu Asn Ile Val Lys Asp
 305 310 315 320
 Leu Pro Phe Glu Pro Ser Lys Lys Leu Tyr Val Val Lys Gln Glu Trp
 325 330 335
 Phe Trp Gly Ser Ile Gln Met Asp Ala Arg Ala Gly Glu Thr Met Tyr
 340 345 350
 Leu Tyr Glu Lys Ala Asn Thr Pro Glu Leu Lys Lys Ser Val Ser Met
 355 360 365
 Leu Ser Leu Asn Thr Pro Asn Ser Asn Arg Lys Arg Arg Arg Leu Lys
 370 375 380
 Glu Thr Leu Ala Gln Leu Ser Arg Glu Thr Asp Val Ser Pro Phe Pro
 385 390 395 400
 Pro Arg Lys Arg Pro Ser Ala Glu His Ser Leu Ser Ile Gly Ser Leu
 405 410 415
 Leu Asp Ile Ser Asn Thr Pro Glu Ser Ser Ile Asn Tyr Gly Asp Thr
 420 425 430
 Pro Lys Ser Cys Thr Lys Ser Ser Lys Ser Ser Thr Pro Val Pro Ser
 435 440 445
 Lys Gln Ser Ala Arg Trp Gln Val Ala Lys Glu Leu Tyr Gln Thr Glu
 450 455 460
 Ser Asn Tyr Val Asn Ile Leu Ala Thr Ile Ile Gln Leu Phe Gln Val
 465 470 475 480
 Pro Leu Glu Glu Glu Gly Gln Arg Gly Gly Pro Ile Leu Ala Pro Glu
 485 490 495
 Glu Ile Lys Thr Ile Phe Gly Ser Ile Pro Asp Ile Phe Asp Val His
 500 505 510
 Thr Lys Ile Lys Asp Asp Leu Glu Asp Leu Ile Val Asn Trp Asp Glu
 515 520 525
 Ser Lys Ser Ile Gly Asp Ile Phe Leu Lys Tyr Ser Lys Asp Leu Val
 530 535 540
 Lys Thr Tyr Pro Pro Phe Val Asn Phe Phe Glu Met Ser Lys Glu Thr

545	550	555	560
Ile Ile Lys Cys Glu Lys Gln Lys Pro Arg Phe His Ala Phe Leu Lys			
565		570	575
Ile Asn Gln Ala Lys Pro Glu Cys Gly Arg Gln Ser Leu Val Glu Leu			
580	585		590
Leu Ile Arg Pro Val Gln Arg Leu Pro Ser Val Ala Leu Leu Leu Asn			
595	600		605
Asp Leu Lys Lys His Thr Ala Asp Glu Asn Pro Asp Lys Ser Thr Leu			
610	615	620	
Glu Lys Ala Ile Gly Ser Leu Lys Glu Val Met Thr His Ile Asn Glu			
625	630	635	640
Asp Lys Arg Lys Thr Glu Ala Gln Lys Gln Ile Phe Asp Val Val Tyr			
645	650		655
Glu Val Asp Gly Cys Pro Ala Asn Leu Leu Ser Ser His Arg Ser Leu			
660	665		670
Val Gln Arg Val Glu Thr Ile Ser Leu Gly Glu His Pro Cys Asp Arg			
675	680		685
Gly Glu Gln Val Thr Leu Phe Leu Phe Asn Asp Cys Leu Glu Ile Ala			
690	695	700	
Arg Lys Arg His Lys Val Ile Gly Thr Phe Arg Ser Pro His Gly Gln			
705	710	715	720
Thr Arg Pro Pro Ala Ser Leu Lys His Ile His Leu Met Pro Leu Ser			
725	730		735
Gln Ile Lys Lys Val Leu Asp Ile Arg Glu Thr Glu Asp Cys His Asn			
740	745		750
Ala Phe Ala Leu Leu Val Arg Pro Pro Thr Glu Gln Ala Asn Val Leu			
755	760		765
Leu Ser Phe Gln Met Thr Ser Asp Glu Leu Pro Lys Glu Asn Trp Leu			
770	775		780
Lys Met Leu Cys Arg His Val Ala Asn Thr Ile Cys Lys Ala Asp Ala			
785	790	795	800
Glu Asn Leu Ile Tyr Thr Ala Asp Pro Glu Ser Phe Glu Val Asn Thr			
805	810		815
Lys Asp Met Asp Ser Thr Leu Ser Arg Ala Ser Arg Ala Ile Lys Lys			
820	825		830
Thr Ser Lys Lys Val Thr Arg Ala Phe Ser Phe Ser Lys Thr Pro Lys			
835	840		845
Arg Ala Leu Arg Arg Ala Leu Met Thr Ser His Gly Ser Val Glu Gly			
850	855	860	
Arg Ser Pro Ser Ser Asn Asp Lys His Val Met Ser Arg Leu Ser Ser			
865	870	875	880

Thr Ser Ser Leu Ala Gly Ile Pro Ser Pro Ser Leu Val Ser Leu Pro
885 890 895

Ser Phe Phe Glu Arg Arg Ser His Thr Leu Ser Arg Ser Thr Thr His
900 905 910

Leu Ile

INTERNATIONAL SEARCH REPORT

International application No
PCT/US01/91868

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) C07K 14/00, G01N 33/53, C12P 21/06 US CL 530/350, 435/320 1, 252 3, 601, 7.1 According to International Patent Classification (IPC) or to both national classification and IPC																				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) US 530/350, 435/320 1, 252 3, 601, 7.1 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EAST, DIALOG																				
C. DOCUMENTS CONSIDERED TO BE RELEVANT																				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No																		
A	Database EMBL, Accession No. Q9H8V3, Isogai et al., "NEDO human cDNA sequencing project", 01 March 2001.	1-13																		
<input type="checkbox"/> Further documents are listed in the continuation of Box C <input type="checkbox"/> See patent family annex																				
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>T</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>N</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*E* earlier document published on or after the international filing date</td> <td>Y</td> <td>document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>A</td> <td>document member of the same patent family</td> </tr> <tr> <td>*U* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	N	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*E* earlier document published on or after the international filing date	Y	document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	A	document member of the same patent family	*U* document referring to an oral disclosure, use, exhibition or other means			*P* document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
A document defining the general state of the art which is not considered to be of particular relevance	N	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
E earlier document published on or after the international filing date	Y	document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
L document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	A	document member of the same patent family																		
U document referring to an oral disclosure, use, exhibition or other means																				
P document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search		Date of mailing of the international search report																		
07 JANUARY 2002		01 FEB 2002																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, DC 20231		Authorized officer <i>Karen Cochran Carlson</i> KAREN COCHRAN CARLSON, PhD																		
Facsimile No (703) 805-9280		Telephone No (703) 805-0190																		